SCHEMBL5009507

SCHEMBL5009507

O=C(O)C1CCN(C2CC(c3ccccc3)C2)C(O)C1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.54
AKR1C1 Q04828 1/20 0.54
SLC18A3 Q16572 6/20 0.43
SIGMAR1 Q99720 4/20 0.43
NOTUM Q6P988 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
GRIN2B Q13224 1/20 0.39
USP5 P45974 1/20 0.39
AGTR2 P50052 1/20 0.39
HSD11B1 P28845 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL444560 0.79 AKR1C3 (0.56) AKR1C3AKR1C1SLC18A3SIGMAR1NOTUM
SCHEMBL1587410 0.78 AKR1C3 (0.54) AKR1C3AKR1C1SLC18A3NOTUMNPC1
SCHEMBL5007409 0.72 AKR1C3 (0.51) AKR1C3AKR1C1NOTUMAGTR2
SCHEMBL5004071 0.72 HRH3 (0.46) AKR1C3AKR1C1SLC18A3SIGMAR1AGTR2
SCHEMBL11665023 0.72 AKR1C3 (0.74) AKR1C3AKR1C1NPC1RAB9AGRIN2B
SCHEMBL717453 0.72 AKR1C3 (0.74) AKR1C3AKR1C1NPC1RAB9AGRIN2B
SCHEMBL7388336 0.72 AKR1C3 (0.74) AKR1C3AKR1C1NPC1RAB9AGRIN2B
SCHEMBL26144401 0.71 AKR1C3 (1.00) AKR1C3AKR1C1SLC18A3SIGMAR1NOTUM
SCHEMBL1073107 0.71 AKR1C3 (1.00) AKR1C3AKR1C1SLC18A3SIGMAR1NOTUM
SCHEMBL17811172 0.71 AKR1C3 (1.00) AKR1C3AKR1C1SLC18A3SIGMAR1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 AKR1C3 1826/4885AKR1C1 2592/4885SLC18A3 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.